A phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors

Cancer

Volumn 92, Issue 5, 2001, Pages 1156-1167

  Penson, Richard T ^a   Supko, Jeffrey G ^a   Seiden, Michael V ^a   Fuller, Arlan F ^a   Berkowitz, Ross S ^b   Goodman, Annekathryn ^a   Campos, Susana M ^b   MacNeill, Kimberley M ^a   Cook, Sarah ^a   Matulonis, Ursula A ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chemotherapy; Clinical trials; Ovarian carcinoma; Pharmacokinetics

Indexed keywords

PACLITAXEL; TOPOTECAN;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; INFECTION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NEUTROPENIA; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTOPENIA; THROMBOSIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TOPOTECAN;

EID: 0035446838     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010901)92:5<1156::AID-CNCR1434>3.0.CO;2-G     Document Type: Article

References (53)

1. Cancer statistics, 1999
2. Chemotherapy of advanced ovarian cancer
3. Progress in gynecologic oncology
4. Taxol (paclitaxel): Mechanisms of action
5. Cell kill kinetics and cell cycle effects of paclitaxel on human and hamster ovarian cell lines
6. Cytotoxic studies of paclitaxel in human tumor cell lines
7. Paclitaxel (Taxol)
8. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms
9. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and Stage IV ovarian cancer
10. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
11. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A Phase I/II trial of 96-hour infusion
12. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: A Phase II pharmakokinetic and pharmacodynamic study in metastatic breast cancer
13. A phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer
14. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colonyforming units in vitro
15. Clinical pharmacokinetics of topotecan
16. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma
17. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
18. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study
19. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion
20. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor
21. Phase I trial of topotecan administered as a 72-hour infusion
22. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120-h continuous infusion
23. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen
24. A phase II study of topotecan given as a continuous 21-day infusion every 28 days in platinum pre-treated ovarian carcinoma
25. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly
26. Prolonged topotecan infusion combined with Doxil® - A well tolerated regimen
27. Computerized quantitation of synergism and antagonism of Taxol, topotecan and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design
28. Reporting results of cancer treatment
29. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of lactone plus carboxylate forms, in human plasma
30. Adaptation of solid phase extraction to an automated column switching method for online sample cleanup as the basis of a facile and sensitive high-performance liquid chromatographic assay for paclitaxel in human plasma
31. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: A Gynecologic Oncology Group study
32. Preparation of mean drug concentration-time curves in plasma. A study on the frequency distribution of pharmacokinetic parameters
33. The jacknife - A review
34. Common noncompartmental pharmacokinetic variables: Are they normally or log-normally distributed?
35. Back to the future: Multiagent chemotherapy in ovarian cancer revisited
36. Topotecan in combination chemotherapy
37. Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens
38. Paclitaxel by 96-hour continuous infusion in combination with cisplatin: A Phase I trial in patients with advanced lung cancer
39. Vinorelbine combined with paclitaxel infused over 96 hours (VI-TA-96) for patients with metastatic breast carcinoma
40. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin
41. Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma
42. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group study
43. Thrombosis with paclitaxel
44. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial
45. Fibrin sheath formation and chemotherapy extravasation: A case report
46. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
47. Novel Taxol formulations: Taxol-containing liposomes
48. Oral efficacy and bioavailability of a novel taxane
49. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion
50. Continuous infusion of low-dose topotecan: Pharmacokinetics and pharmacodynamics during a Phase II study in patients with small cell lung cancer
51. Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in Stage IV breast cancer
52. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines
53. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: Preclinical identification of suitable drug partners to taxotere, Taxol, topotecan and gemcitabine